SUNNYVALE, California — Accuray Incorporated (Nasdaq: ARAY) announced today that the first patient treatment has been completed using the CyberKnife® M6™ System with the InCise™ Multileaf Collimator (MLC). The treatment was administered as a multidisciplinary effort between Dr.Steven Burton from the Department of Radiation Oncology and Dr. Johnathan Engh from the Department of Neurosurgery at UPMC in Pittsburgh, Pennsylvania. UPMC was one of the InCise MLC evaluation sites working in collaboration with Accuray.
"We have successfully treated the first patient using the CyberKnife M6 System with the InCise MLC. The patient, diagnosed with a brain meningioma, was a typical candidate for highly-focused treatment that can be delivered by the CyberKnife," said Dr.Dwight E. Heron MD, FACRO, FACR, Director of Radiation Services. "With the addition of the MLC, we were able to achieve equivalent precision in tumor targeting and sparing of healthy tissue, but it took us less than half the time -- just under 22 minutes -- to complete a traditional one hour treatment. The treatment time includes continuous imaging throughout the procedure to ensure accurate dose delivery and the actual time spent delivering the radiation. This real-world case is consistent with our InCise MLC technical evaluation experience and exceeded our expectations in its efficiency."
The M6 Series delivers radiosurgery and stereotactic body radiation therapy, enabling precise, high-quality dose distributions to be confidently administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The system is able to adjust and automatically stay on target in real-time, accounting for patient and tumor motion. CyberKnife is the only robotic radiosurgery system available today which delivers such high precision treatments for intra- and extra-cranial disease sites throughout the body.
"We congratulate Dr. Heron, Dr. Huq and their team on treating the first patient using the CyberKnife M6 System and InCise MLC," saidJoshua H. Levine, president and chief executive officer of Accuray. "With the addition of the MLC, clinicians can deliver the same precise radiosurgery treatments they have come to expect with the CyberKnife System, while significantly reducing treatment times, for a wider range of tumor types, including larger and different kinds of tumors than were previously treated."
About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.